CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

If insulin glargine was prescribed, a vial was dispensed regardless of the treatment group because it was not available in a pen device at the start of the study.

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. First ...

A total of 19 patients in the insulin pen group (54%) and 18 patients in the vial and syringe group (45%) received insulin glargine during hospitalization. Eighteen patients in the insulin pen ...

Smart insulin pens are expected to drive the insulin pen market from $13.8 billion in 2020 to more than $16 billion by 2030, according to GlobalData.

Civica will make generic versions of the three most popular brands of insulin — Lantus, Humalog and Novolog, which account for more than 80% of the U.S. market.

The insulin headed to California will be branded as CalRx. Residents of the state can expect to pay the same out-of-pocket costs as Civica customers in the rest of the country.

At week 52, the mean total weekly insulin dose was 289.1 U per week with efsitora and 332.8 U per week with glargine (estimated between-group difference, −43.7 U per week; 95% CI, −62.4 to − ...